Tag: Cx601

March 9, 2017 Off

TiGenix’s Chron’s disease treatement Cx601 consistent after two years study

TiGenix’s study of Cx601 showed that results after two years are consistent with the results communicated at week 24 and week 52, said Dr Marie Paule Richard, Chief Medical Officer of TiGenix.

March 7, 2017 Off

TiGenix’s ammended trial for Cx601 Chron’s disease accepted in US, kicks off in next four months

By Dino Mustafić

Belgian-headquartered biopharmaceutical company TiGenix has received positive feedback from the U.S. Food and Drug Administration (FDA) for its improved phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.